Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | BRPF1 | P55201 | 4/20 | 0.34 |
| ▸ | BRD1 | O95696 | 2/20 | 0.34 |
| ▸ | BRPF3 | Q9ULD4 | 1/20 | 0.34 |
| ▸ | THRB | P10828 | 2/20 | 0.33 |
| ▸ | EGFR | P00533 | 1/20 | 0.32 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.31 |
| ▸ | BRD4 | O60885 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | DRD2 | P14416 | 2/20 | 0.31 |
| ▸ | DRD1 | P21728 | 2/20 | 0.31 |
| ▸ | DRD4 | P21917 | 2/20 | 0.31 |
| ▸ | DRD5 | P21918 | 2/20 | 0.31 |
| ▸ | DRD3 | P35462 | 2/20 | 0.31 |
| ▸ | TTR | P02766 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31248757 | 0.83 | SMN1; SMN2 (0.37) | MEN1KMT2AL3MBTL1BRPF1EGFR | |
| SCHEMBL31248652 | 0.83 | MEN1 (0.34) | MEN1KMT2AL3MBTL1BRPF1EGFR | |
| SCHEMBL26547632 | 0.81 | CYP19A1 (0.43) | MEN1KMT2AL3MBTL1BRPF1THRB | |
| SCHEMBL26547726 | 0.77 | KMT2A (0.34) | MEN1KMT2AL3MBTL1BRPF1EGFR | |
| SCHEMBL31248639 | 0.77 | KMT2A (0.34) | MEN1KMT2AL3MBTL1BRPF1EGFR | |
| SCHEMBL31393691 | 0.76 | EGFR (0.36) | EGFRDRD2DRD4DRD3SMN1; SMN2 | |
| SCHEMBL31248637 | 0.76 | BRPF1 (0.43) | MEN1KMT2AL3MBTL1BRPF1EGFR | |
| SCHEMBL31248926 | 0.75 | BRPF1 (0.33) | BRPF1BRD1BRPF3THRBHDAC8 | |
| SCHEMBL26547732 | 0.74 | ACACB (0.38) | MEN1KMT2AL3MBTL1BRPF1EGFR | |
| SCHEMBL31248918 | 0.74 | DRD2 (0.36) | BRPF1BRD1BRPF3THRBDRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4720057-A2 | COMPOUNDS AND COMPOSITIONS AS CBP/P300 DEGRADERS AND USES THEREOF | Oncopia Therapeutics, Inc. D/B/A SK Life Science Labs (US) | 2026-04-08 | — | — | EP | disclosed |
| US-20250114345-A1 | COMPOUNDS AND COMPOSITIONS AS CBP/P300 DEGRADERS AND USES THEREOF | ONCOPIA THERAPEUTICS, INC. D/B/A/ SK LIFE SCIENCE LABS | 2025-04-10 | — | — | US | disclosed |
| WO-2025049976-A1 | COMPOUNDS AND COMPOSITIONS AS CBP/P300 DEGRADERS AND USES THEREOF | ONCOPIA THERAPEUTICS, INC. D/B/A SK LIFE SCIENCE LABS (US) | 2025-03-06 | — | — | WO | disclosed |
| WO-2025049994-A1 | COMPOUNDS AND COMPOSITIONS AS CBP/P300 DEGRADERS AND USES THEREOF | ONCOPIA THERAPEUTICS, INC. D/B/A SK LIFE SCIENCE LABS (US) | 2025-03-06 | — | — | WO | disclosed |
| WO-2024249888-A2 | COMPOUNDS AND COMPOSITIONS AS CBP/P300 DEGRADERS AND USES THEREOF | ONCOPIA THERAPEUTICS, INC. D/B/A SK LIFE SCIENCE LABS (US) | 2024-12-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250114345-A1 | COMPOUNDS AND COMPOSITIONS AS CBP/P300 DEGRADERS AND USES THEREOF | EP300, CREBBP, HDAC1 | MEN1 2485/4885KMT2A 689/4885L3MBTL1 2199/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.